GEKO Venous Thromboembolism Prevention Study

Exclusion Criteria16

• Inability to gain consent from the patient, or a declaration from a Personal Consultee or Nominated Consultee
• Unwitnessed onset with a long lie on the floor before admission
• Clinically apparent deep vein thrombosis at screening
• Patient is expected to require palliative care within 14 days
• Patient does not live in the local catchment area and is expected to be transferred to their local hospital for on-going care.
• Patient has recently been involved in or is currently involved in a clinical trial for either a medical device or medicinal product, within the past 3 months, with the exception: if co-enrolment is not considered to impact adverse events or outcomes in the opinion of the Chief Investigator. (A live document containing a list of approved studies will be included in a reference document made available to all study sites and available upon request)
• Contraindications for the use of the geko™ device:
• Allergy to hydrogel constituents
• Contraindications to IPC:
• Severe peripheral vascular disease
• Large leg ulcers requiring extensive bandaging (small ulcers or skin breaks with flat coverings are not an exclusion)
• Severe oedema
• Leg deformities making appropriate fitting impossible
• Uncontrolled congestive cardiac failure
• Pregnancy
• Single or double leg amputations